European Pharmaceutical Review
SEPTEMBER 28, 2023
There has been a steady stream of developments in the vaccine manufacturing space throughout 2023. A notable milestone was Moderna’s announcement in April that it had, following finalisation of a ten-year strategic partnership with the UK Government, commenced construction of its mRNA vaccine manufacturing technology centre.
European Pharmaceutical Review
OCTOBER 12, 2023
September 2023 saw a wave of new pharmaceutical manufacturing facility expansions and launches across Europe. Research by the Confederation of British Industry (CBI) , released in September this year, highlighted progress for UK manufacturing in its latest Industrial Trends Survey. Meath opened last month.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
JULY 21, 2023
In this Q&A EPR speaks to Naser Al Yammahi the Deputy CEO of Hayat Biotech about pharmaceutical supply chain challenges and how they can be addressed. Yammahi was instrumental in building Hayat’s extensive distribution network needed to supply vaccines during the COVID-19 pandemic.
Clarify Health
OCTOBER 26, 2021
Not Enrolled Given this historical backdrop, the FDA and leading biotech and pharmaceutical manufacturers have taken initiatives to ensure: representative clinical trial recruitment that reflects the broader US patient population and equitable access to therapies and vaccines. J National Comprehensive Cancer Network.
pharmaphorum
DECEMBER 16, 2022
Compounding the situation to understand how such an outcome was allowed to occur is the fact that many deals between government and pharmaceutical companies selling the treatments and vaccines were agreed under terms of confidentiality.
European Pharmaceutical Review
APRIL 18, 2023
billion and another 200 new jobs is planned for Eli Lilly and Company’s two new pharmaceutical manufacturing sites in Boone County, US. Eli Lilly’s investment here is the largest manufacturing investment at a single location in its history. Students will also be able to access a smart manufacturing lab.
pharmaphorum
OCTOBER 26, 2022
The status isn’t awarded lightly and Chiesi is the largest pharmaceutical manufacturer to be named a B Corp. “We As a result, society and government bodies have not developed models and policies that adequately support the development of and access to rare disease drugs.”.
Expert insights. Personalized for you.
81 
Let's personalize your content